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The latent membrane protein LMP1 of Epstein-Barr virus (EBV) is often present in EBV-associated
malignancies including nasopharyngeal carcinoma and Hodgkin’s lymphoma. Previous work demonstrates
that the LMP1 gene of EBV is sufficient to transform certain established rodent fibroblast cell lines and to
induce the tumorigenicity of some human epithelial cell lines. In addition, LMP1 plays pleiotropic roles in cell
growth arrest, differentiation, and apoptosis, depending on the background of the target cells. To examine the
roles of LMP1 in cell proliferation and growth regulation in primary culture cells, we constructed a recom-
binant retrovirus containing an LMP1 gene. With this retrovirus, LMP1 was shown to stimulate the prolif-
eration of primary mouse embryonic fibroblasts (MEF cells). It has a mitogenic activity for MEF cells, as
demonstrated by an immediate induction of cell doubling time. In addition, it significantly extends the passage
number of MEF cells to more than 30 after retroviral infection, compared with less than 5 for uninfected MEF
cells. Furthermore, LMP1 cooperates with a p16-insensitive CDK4R24C oncogene in transforming MEF cells.
Our results provide the first evidence of the abilities of the LMP1 gene, acting alone, to effectively induce the
proliferation of primary MEF cells and of its cooperativity with another cellular oncogene in transforming
primary cells.
Epstein-Barr virus (EBV) is a human gammaherpesvirus
commonly carried in the majority of the human population. It
is the causative agent for proliferative diseases such as infec-
tious mononucleosis and oral hairy leukoplakia in AIDS pa-
tients. It is also implicated in a variety of human malignancies
that include Burkitt’s lymphoma, nasopharyngeal carcinoma,
Hodgkin’s lymphoma, nasal T-cell lymphoma, and immuno-
blastic lymphomas in posttransplant and AIDS patients (39).
The virus often adopts latent forms in EBV-associated cancers.
In nasopharyngeal carcinoma and Hodgkin’s lymphoma, type
II latency gene expression was observed. During this type II
latency, only three viral proteins are routinely detected: EBV
nuclear antigen 1 (EBNA1) and two latent membrane proteins,
LMP1 and LMP2. Among the three EBV genes, the LMP1 gene
is the only one implicated in cell immortalization and transfor-
mation. It is one of the viral genes required for B-cell immortal-
ization, together with the EBNA2, EBNA3a, and EBNA3c genes
(8, 15, 22, 23, 48). In addition, LMP1 has been shown to induce
the transformation of certain established rodent fibroblast cell
lines, including Rat-1 and BALB/c 3T3 (2, 33, 49). Furthermore,
LMP1 induces the morphological transformation of the RHEK-1
cell line (12) and the tumorigenicity of epithelial cell lines in
severe combined immunodeficient mice (18, 36).
Although EBV is an important oncogenic virus in human, the
LMP1 genes appeared to act differently from oncogenic genes of
other DNA oncogenic viruses, including simian virus 40 (SV40)
large T antigen, adenovirus E1A and E1B, and human papillo-
mavirus (HPV) E6 and E7. There is little evidence suggesting that
the LMP1 gene can function similarly to these viral oncogenes or
even a cellular oncogene such as ras or myc. Though LMP1
transforms several immortalized rodent fibroblast cell lines and
participates in B-cell immortalization, a single LMP1 gene has not
been shown to induce continuous proliferation of any primary cell
culture. Similarly, although it cooperates with a number of EBV
genes in inducing B-cell proliferation, there is no report on the
cooperativity of the LMP1 gene with another cellular oncogene in
transforming primary cells.
Protein sequence analysis of LMP1 revealed at least three
domains: an amino-terminal cytoplasmic domain of 20 amino
acid residues, a six-transmembrane domain of 185 amino acid
residues, and a carboxy-terminal cytoplasmic domain of 200
amino acid residues (24). The six-transmembrane domain was
shown to be required to form cytoplasmic membrane patches.
The oligomerization of LMP1 in the cytoplasmic membrane
may mimic that of other membrane receptor molecules in-
duced by ligand-receptor interactions, resulting in constitutive
activation of the LMP1 signaling pathway (14). The C-terminal
cytoplasmic region was shown to interact with two families of
proteins, TRAF (tumor necrosis factor [TNF] receptor-associ-
ated factor) and TRADD (TNF receptor-associated death do-
main), through two distinct domains (21, 34). These two do-
mains participate in NF-kB activation (19, 32) and in the
transformation of primary B cells with other EBV genes (20, 21).
Other recent studies suggest that LMP1 can also induce the ac-
tivation of c-Jun N-terminal kinase (JNK), resulting in the induc-
tion of AP1 activity of the transfected cells (11, 25). However,
JNK and AP1 activations were also reported for the TNF signal-
ing pathway responsible for the suppression of apoptosis (1). The
roles of JNK and AP1 activation in LMP1-mediated cellular pro-
liferation and transformation remain to be elucidated.
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ology, The University of Hong Kong, Pathology Building, Queen Mary
Hospital, Hong Kong, People’s Republic of China. Phone: 852-2855-
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To understand the roles of LMP1 in cell proliferation and
growth regulation in primary culture cells, we used a retrovirus to
deliver LMP1 in the primary mouse embryonic fibroblast (MEF
cell) model system. This approach allowed the integration and
stable expression of LMP1 gene in the target cells at a high
efficiency, thus permitting continuous analysis of the effect of
LMP1 in primary culture cells in the absence of any drug selec-
tion. The results of our study indicate that LMP1 alone is suffi-
cient to induce the proliferation of MEF cells. It has a mitogenic
activity for MEF cells and is capable of significantly extending
their passage numbers in culture. Furthermore, although LMP1
fails to cooperate with the ras oncogene to transform MEF cells,
it cooperates with the CDK4R24C oncogene (46) to do so.
MATERIALS AND METHODS
Retroviral plasmids. A 1.95-kb fragment containing a full-length LMP1 gene
(pLMP1 [6]) was removed and inserted into the BamHI site of pcDNA3 to give
pcDNA3-LMP1. The LMP1 fragment then was isolated with HindIII and EcoRV
digests and cloned into HindIII and ClaI sites of the retroviral vector pLNSX
(31) to generate pLNSX-LMP1. Other retroviral plasmids used in the study are
pBabe-Ras with an active form of human H-rasV12 cDNA (46) and pWZL-R24C
with a p16-insensitive CDK4R24C oncogene (46).
Cell culture and preparation of MEF cells. Cell culture was carried out in
Dulbecco modified Eagle medium supplemented with 10% fetal bovine serum
(GIBCO). PA317 and Bosc23 (American Type Culture Collection) are ampho-
tropic and ecotropic retrovirus packaging cell lines, respectively. To produce MEF
cells for the experiment, day 14 embryos were obtained from pregnant BALB/c mice.
After removal of the head and red organs, the torso was minced and digested with
0.1% trypsin and 0.1% collagenase for 30 min at 37°C. The cells were seeded onto
10-cm cell culture dishes and split once at 1:4 before being frozen. For retroviral
infections, the cells were thawed and split once more prior to infection.
Gene transfer mediated by retrovirus. To obtain retroviruses, the retroviral
plasmids were transfected into the ecotropic retrovirus packaging cell line
Bosc23 with Lipofectin (GIBCO). After 15 h of incubation at 37°C, cells were
placed in fresh medium and further incubated for 48 h. The virus-containing
supernatants were collected at this time and again 12 h later. After filtering
through 0.45-mm-pore-size filters (Millipore), the viral stocks were supplemented
with Polybrene (8 mg/ml; Sigma). The viruses were then used to infect the
amphotrophic viral packaging cell line PA317. After 24 h of infection, the
infected PA317 cells were selected with the appropriate drug: puromycin (2
mg/ml) for pBabe, geneticin (500 mg/ml) for pLNSX, or hygromycin (200 mg/ml)
for pWZL. Two or three weeks later, the resistant cells were collected and
expanded as the virus-producing cell lines. To produce the viral stock, fresh
medium was added to the virus-producing cells and incubated for 24 to 48 h. The
virus-containing supernatants were collected and filtered as before. After sup-
plementation with Polybrene (4 mg/ml), the supernatants were used fresh as viral
stocks or aliquoted and stored at 280°C. Characterization and titration of the
viruses were carried out with appropriate drug selections, immunofluorescence,
and Western blotting with appropriate antibodies. Most of the viral stocks have
titers ranging from 1 3 105/ml to 4 3 105/ml. In a typical experiment, Rat-2 or
REF52 cells (5 3 105 per well) were seeded into six-well plates the day prior to
infection. A fixed volume of a viral stock was used to infect the target cells for
48 h. LMP1-expressing virus-infected (MEF-LMP1) cells were trypsinized and
seeded onto eight-well slides for immunofluorescence analysis by using mono-
clonal antibody S12, specific for LMP1, to determine the viral titer. Similar
results were obtained with a number of mouse fibroblast and human epithelial
cell lines. For all subsequent experiments, MEF cells were plated at 2 3 105 cells
per well in six-well plates and incubated with an appropriate viral stock over-
night. The culture medium was then replaced with another viral stock in the
coinfection studies and incubated for another 8 h. The infected MEF cells,
regarded as passage 1 (P1), were subcultured in normal medium without drug
selection and split 1:4 when they reached confluence.
Cell growth analysis. For cell growth curves, 2,000 cells were seeded per well
into 24-well microtiter plates 24 h after viral infections. At the indicated time
points, the cells were removed with trypsin digestion and the number of cells was
counted. The experiment was done in triplicate to determine the number of cells
at each time point and standard deviation. This experiment was reproduced twice.
Soft agar assay. For soft agar assay, infected MEF cells at P3 or P6 were
seeded into semisolid agarose medium (Dulbecco modified Eagle medium sup-
plemented with 10% fetal calf serum) and low-melting-point agarose (base layer,
0.6%; upper layer, 0.35%) at a density of 4 3 103 cells per well in six-well plates
(Nunc). The cells were fed each week with several drops of fresh medium placed
directly onto the surface of the upper layer. After 2 to 3 weeks of incubation at 37°C,
foci were viewed and counted. Photographs were taken under a microscope for
analysis of representative colonies or with a regular camera after staining of the
dishes with Giemsa and destaining with 50% ethanol in phosphate-buffered saline.
Immunoblot analysis. Cells were collected and then washed with ice-cold
phosphate-buffered saline and lysed in NP-40 lysis buffer (5). Cell lysates were
made and analyzed for protein concentration by the Bradford assay (Bio-Rad).
Then 100-mg aliquots of protein lysates were mixed with sample buffer and boiled
for 5 min; they were then separated on sodium dodecyl sulfate–10% polyacryl-
amide gels and transferred to nitrocellulose membranes by electroblotting. West-
ern blotting with a monoclonal antibody against LMP1 (S12) or an antibody
against CDK4 (H-303; Santa Cruz) was followed by detection with an ECL
(enhanced chemiluminescence) detection kit (Amersham).
Telomerase activity assay. Telomerase activity was determined by TRAP assay
(7). To minimize the effect of telomerase inhibitors that may have been present
in the sample extract, each specimen was assayed at two concentrations (1-fold and
10-fold dilutions). For an RNase control, the lysate was preincubated with 0.5 mg of
DNase-free RNase at room temperature for 15 min before the TRAP assay.
RESULTS
The LMP1 gene is effectively introduced into MEF cells via
retrovirus. To effectively introduce LMP1 into primary culture
fibroblasts and monitor the cells continuously without the se-
lective pressure of drugs, an LMP1-expressing retrovirus (v-
LMP1) was generated and evaluated in Rat-2 cells by immu-
nofluorescence and immunoblotting using a specific mouse
monoclonal antibody against LMP1, S12 (30) or CS1-4 (42).
We estimated that our optimized infection condition routinely
resulted in infection of about 50% of the cells. Further study
revealed that the v-LMP1 stocks were also capable of effec-
tively infecting mouse fibroblast, human diploid fibroblast
(IMR90), and human epithelial cell lines (data not shown).
To analyze the effects of LMP1 on primary MEF cells, v-
LMP1 was then used to infect the cells. These P1 cells were
then cultured in medium without drug selection and split 1:4
upon reaching confluence. After two additional passages, the
lysates of cells at P3 were analyzed by Western blotting and
immunofluorescence with LMP1 antibody S12. Western blot
results revealed two prominent immunoreactive bands with
molecular masses of 60 and 43 kDa that were specifically de-
tected from the lysates of v-LMP1-infected MEF cells, identi-
cal to those from the lysate of EBV-positive B95-8 cells (42)
(Fig. 1). The Western blot result is consistent with previous
findings for LMP1 protein. The 60-kDa band is the full-length
LMP1, and the smaller 43-kDa band is likely a breakdown
product. Both bands are absent in the EBV-negative lympho-
blastic leukemia cell line MOLT-4 or in MEF cells infected
with a vector retrovirus (v-LNSX). LMP1 proteins in v-LMP1-
infected MEF cells are primarily full length. The stability of
LMP1 appears to be a feature of the LMP1 gene used in the
retrovirus and independent of the types of cells used for the
infections (data not shown).
The retrovirus provided a good system for introducing
LMP1 into MEF cells. At P3, over 90% of v-LMP1-infected
MEF cells expressed LMP1, seen in the cytoplasm or on the
cell surface in small aggregations, whereas the v-LNSX-in-
fected MEF cells were negative in the assay (Fig. 2A and B).
The total amount of LMP1 in v-LMP1-infected MEF cells was
substantially higher than that in B95-8 cells, as indicated by
their relative intensities in Western blot analysis of sequentially
diluted lysates (Fig. 1). This difference may be partly due to the
observation that the majority of v-LMP1-infected MEF cells
expressed LMP1 at P3, whereas a significantly smaller percent-
age of our cultured B95-8 cells were positive for LMP1 in the
immunofluorescence assay (Fig. 2C). The negative control
MOLT-4 cells were negative for LMP1 (Fig. 2D).
The level of LMP1 expressed in v-LMP1-infected MEF cells
was stable for up to 30 passages after infection in the absence
of any drug selection, as indicated by Western blot results for
LMP1 (Fig. 3). In addition, the immunofluorescence of MEF-
LMP1 cells at P24 revealed that virtually all cells were positive
for LMP1 (data not shown). Thus, this retroviral system pro-
vided an effective way to stably introduce and express LMP1 in
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primary fibroblasts. The result further suggested the absence of
cellular toxicity of LMP in primary MEF cells, as it was ex-
pressed in more than 90% of the cells starting from P3 (Fig.
2A), and the level of expression was stable throughout the
course of the experiment (Fig. 3). In contrast, there appeared
to be a growth advantage for LMP1-expressing MEF cells since
only about 50% of the infected cells expressed LMP1 imme-
diately following v-LMP1 infection, at the end of P1. Two
passages later (P3), 90% of the MEF were positive for LMP1
in the absence of drug selection. Interestingly, expression of
LMP1 was correlated with increasing passage numbers of MEF
cells, which normally can be passaged only a few times in
culture before reaching senescence.
LMP1 induces the proliferation of MEF cells associated
with extended passage numbers. The effects of LMP1 on pri-
mary fibroblast cells were studied by infecting MEF cells with
v-LMP1 or with v-LNSX as a negative control. The virus-
infected cells were subsequently pooled and repeatedly subcul-
tured whenever they reached confluence, which usually took
about 1 week at early passages. Immediately after infection
with retroviruses, all cell cultures presented the typical mor-
phology of primary fibroblasts (Fig. 4A). The v-LNSX-infected
cells had a low plating efficiency and grew slower with each
additional passage, similar to the uninfected MEF cells. The
cells gradually adopted a flatter and enlarged shape suggestive
of an aging process. By P4 (12 population doublings), most
v-LNSX-infected cells reached a senescence stage and could
not be passaged further (Fig. 4B). The v-LMP1-infected MEF
cells, however, behaved very differently from the v-LNSX neg-
ative control. Although v-LMP1-infected cells exhibited a mor-
phology and growth rate similar to those of the v-LNSX con-
trol during P1, they displayed significant differences in both
cellular morphology and proliferating ability at P2 and P3. The
cells exhibited a higher plating efficiency and more vigorous
growth with an apparently higher growth rate. In addition, the
morphology of the cells changed to smaller and a long spindle
shape, and the population gradually became relatively homo-
geneous, as indicated by a photo of MEF at P10 (Fig. 4C).
Furthermore, it was clear that MEF-LMP1 cells can be pas-
saged much further than MEF-LNSX cells. While uninfected
MEF cells and MEF-LNSX cells were passaged fewer than five
times, MEF-LMP1 cells had been subcultured for more than
30 passages and apparently could be readily passaged further.
The result that LMP1 induced the proliferation of MEF cells
was reproducible in a total of four independent experiments
using MEF cells from two sets of mouse embryos over the
course of 1 year. While the v-LNSX-infected MEF cells reached
senescence before P6 in all experiments, the v-LMP1-infected
MEF cells have been consistently passaged further. At present
they have undergone 35, 22, 13, and 12 passages in these four
experiments, and all maintain vigorous growth. Thus, the LMP1
gene alone is sufficient to induce the extended proliferation of
MEF cells by significantly increase their passage numbers in vitro.
LMP1 stimulates the growth rate of MEF cells. It was ap-
parent that the v-LMP1-infected MEF cells grew faster than
the v-LNSX-infected cells starting from P2, one passage away
from the initial infections. To analyze the mitogenic effects of
LMP1 on MEF cells, we examined the growth rates of MEF
cells infected with v-LMP1 or v-LNSX by plating out the cells
at the end of P1 into 24-well plates at a density of 2,000 cells
per well. The cells were further incubated for growth analysis
in a triplicate experiment in the absence of drug selection. At
fixed time intervals, the cells were harvested and cells per well
were counted for 8 days since the MEF-LMP1 cells nearly
reached confluence by day 8. The results indicate that v-LMP1-
infected cells grew substantially faster than v-LNSX-infected
MEF cells (Fig. 5). The LMP1-expressing cells have a doubling
time of about 3 days, whereas the vector control cells double
every 4.5 days at this passage. However, it should be noted that
the growth of MEF cells in vitro is a dynamic process, and cell
growth became slower with each additional passage as though
the cells were going through a rapid aging process. The results
presented suggest that LMP1 has an immediate mitogenic ef-
fect on MEF cells in addition to its ability to significantly
extend their passage numbers.
LMP1 cooperates with CDK4R24C in transforming MEF
cells. Although LMP1 induces the extended proliferation and
increased growth rate of MEF cells, the MEF-LMP1 cells were
not transformed even after 30 passages, as they preserved
contact inhibition for growth on plates and failed to grow in
soft agar (data not shown). In fact, most cellular and viral
oncogenes are not capable of transforming primary MEF cells
alone, and the cooperative transformation of primary murine
fibroblast cells between oncogenes is an important feature of
them. However, little information is available about the ability
of LMP1 to cooperatively transform primary cells with any
other cellular oncogene. Such cooperative transformation may
be important as an indication of the roles of LMP1 in a mul-
tistep process of carcinogenesis, and it may provide a genetic
model system with which to delineate the mechanism or path-
way involved in LMP1-mediated transformation. To address
the role of LMP1 in cooperatively transforming primary rodent
fibroblast cells, retroviruses containing constitutive active H-
rasV12 (v-H-rasV12 [46]) and p16-insensitive CDK4R24C (v-
CDK4R24C [46]) genes were used in the cotransformation as-
say. A previous experiment indicated that LMP1 could mediate
ERK1/2 activation in Rat-1 fibroblasts via a Ras-dependent
pathway (40). Activated Ras and ERK1/2 can result in the
up-regulation of cyclin D1 expression (28). The second
oncogene, CDK4R24C, was originally identified in human mel-
anomas with an arginine-to-cysteine exchange at residue 24
(51). This mutation prevents the binding of CDK4 to its inhib-
itor p16INK4a. As a result, CDK4R24C forms a complex with
cyclin D1, and the CDK4R24C-cyclin D1 complex is resistant to
the inhibition of p16INK4a in vivo (3).
As indicated above, a single LMP1 gene did not induce cell
transformation. Similarly, the MEF cells coinfected with v-
FIG. 1. Western blot analysis of LMP1 in MEF cells after infection with
v-LMP1. MEF cells were infected with either v-LNSX (MEF-Vector) or v-LMP1
(MEF-LMP1) and passaged twice before collected for analysis (P3). B95-8 is an
EBV-positive marmoset B-lymphocyte cell line that expresses LMP1, and
MOLT-4 is an EBV-negative lymphoblastic leukemia cell line. Cell lysates were
made, and 100 mg of protein was loaded in each lane for Western blot analysis
unless otherwise indicated. To compare the relative levels of LMP1 in MEF-
LMP1 and B95-8 cells, two- and fourfold dilutions of both lysates were made and
analyzed. A mouse monoclonal antibody against LMP1, S12, was used for the
immunoblot.
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LMP1 and v-H-rasV12 (MEF-LMP1-Ras cells) also had an ex-
tended passage number, although they did not present any
degree of morphological transformation at P10 in two experi-
ments (Fig. 4D). v-H-rasV12 is functional since it transformed
both NIH 3T3 and Rat-1 fibroblasts (data not shown), and we
have found that it induces an immediate premature senescence
of MEF cells (reference 46 and data not shown). The presence
of v-H-rasV12 in MEF-LMP1-Ras cells was verified by the ac-
quired resistance of a large percentage (30 to 50%) of the
coinfected cells to puromycin (from pBabe-Ras) at P10. In
contrast, both MEF cells (P3) and MEF cells infected with
v-LMP1 alone (P10) were sensitive to puromycin.
Interestingly, several cell clones (4 and 19 in two experi-
ments) with distinct morphology emerged only from cells coin-
fected with v-LMP1 and v-CDK4R24C, displaying an apparent
morphological transformation at P3 on cell culture plates, ap-
proximately 2 to 3 weeks after coinfection. The cells became
shorter and much smaller, and they grew much faster than all
other infected cells. By P5, the entire population was largely
taken over by these apparently transformed cells. At P10, the
entire cell population exhibited a complete morphological
transformation (Fig. 4F) that was not seen for cells infected
with v-CDK4R24C (Fig. 4E). Although v-CDK4R24C-infected
cells exhibited a slightly extended life span, they never exhib-
ited this transforming morphology. In fact, the v-CDK4R24C-
infected cells in two experiments were passaged once more
(P5) and could not be passaged further. Thus, LMP1 specifi-
cally cooperates with CDK4R24C in inducing cellular morpho-
logical transformation of primary MEF cells.
To further examine the transformation properties of cells
FIG. 2. Immunofluorescence analysis of v-LMP1-infected MEF cells. Cells were immunostained with LMP1 antibody S12 and counterstained with propidium iodide
for nuclei. (A) MEF cells infected with v-LMP1 and subcultured twice (P3) before staining with S12 antibody for LMP1 expression. The green sparkles represent LMP1
proteins localized in cytoplasm or on cytoplasmic membrane. (B) MEF cells infected with control virus v-LNSX (P3). (C) B95-8 cells stained with S12 as the positive
control. About 5 to 10% of our cultured cells were positive for LMP1. The positive signal is yellow due to the combined effect of green and red fluorescence. (D)
MOLT-4 cells stained with S12 as the negative control.
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coinfected with v-LMP1 and v-CDK4R24C, a soft agar assay was
performed to demonstrate the anchorage-independent growth
of these cells. About 15% (610 and 650 of 4,000 cells plated in
two separate experiments) of the cells coinfected with v-LMP1
and v-CDK4R24C at P6 were capable of producing foci in the
soft agar assay (Fig. 6F), confirming that they were trans-
formed cells. In contrast, none of the four individual retro-
viruses, v-LNSX (P3), v-LMP1 (P6), v-H-rasV12 (P3), or
v-CDK4R24C (P3), resulted in any focus formation in soft agar,
nor did v-LMP1 and v-H-rasV12 coinfection (P6) (Fig. 6A to E).
Cells at a different passage (P3) were used in some cases due
to the limited passage numbers of the primary fibroblasts since
none of the infected MEF cells without v-LMP1 could be
passaged beyond P5. Thus, the results of the soft agar assay
indicate that LMP1 cooperates with the CDK4R24C gene but
not the H-rasV12 gene in transforming MEF cells.
Like that of v-rasV12, the presence of both v-LMP1 and
v-CDK4R24C in MEF cells was confirmed by the acquired re-
sistance of the infected cells to geneticin and hygromycin,
respectively. It is interesting that the MEF cells coinfected with
v-LMP1 and v-CDK4R24C were the only ones resistant to both
geneticin (for v-LMP1) and hygromycin (for v-CDK4R24C [46])
at P10, and they were resistant to both drugs despite the ab-
sence of any prior selection. In addition, Western blot results
with anti-LMP1 antibody S12 revealed the expression of LMP1
FIG. 3. The expression of LMP1 in v-LMP1-infected MEF cells is stable in
the absence of drug selection. The cell lysates were obtained from MEF cells
infected with v-LNSX (MEF-Vector) or v-LMP1 (MEF-LMP1) at P3, P11, and
P30 following infection with v-LMP; 100 mg of protein was loaded in each lane
for Western blot analysis with antibody S12. B95-8 is an EVB-positive cell line,
and MOLT-4 is an EBV-negative cell line. Western blotting against b-actin was
used as the loading control.
FIG. 4. LMP1 extends the passage number of MEF cells and induces a morphological transformation of the cells in cooperation with CDK4R24C. (A) P1 MEF cells
infected with v-LNSX. (B) P4 MEF cells infected with v-LNSX. Cells are flat and enlarged, indicating that they are approaching senescence. This is the last passage
that can be routinely obtained with MEF-LNSX cells. (C) P10 MEF cells infected with v-LMP1. Cells are smaller, with a long spindle shape. They have a higher plating
efficiency and grow continuously. (D) P10 MEF cells coinfected with v-LMP1 and v-H-rasV12. Their morphology and growth properties are similar to those of
v-LMP1-infected cells. (E) P4 MEF infected with v-CDK4R24C. The cells were further passaged once before they stopped dividing. (F) P10 MEF cells coinfected with
v-LMP1 and v-CDK4R24C. The cells exhibit a transforming morphology characterized by smaller and shorter cells with a high density. They are the most actively
proliferating cells.
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from cell lysates of all v-LMP1-infected MEF cultures (Fig.
7A). Furthermore, an increased level of CDK4 protein could
be detected in MEF cells infected with v-CDK4R24C (Fig. 7B).
Thus, the results suggested that cointroduction of the EBV
LMP1 and cellular CDK4R24C oncogenes resulted in the trans-
formation of primary mouse fibroblasts.
MEF cells infected with v-LMP1 were negative for telomer-
ase. As indicated above, none of the MEF cells infected with
v-LNSX, v-H-rasV12, or v-CDK4R24C could be passaged beyond
P5 in the experiment presented. Because LMP1 is associated
with extended passage numbers of MEF cells, we examined
whether the proliferative MEF-LMP1 cells were positive for
telomerase. Cell lysates from parent MEF cells and from MEF
infected with v-LMP1 at P10 were examined for telomerase
activity (Fig. 8). HeLa cell lysate was used as a positive control
to indicate the sensitivity of the assay and its specificity after
treatment of the lysate with RNase. The result indicated that
v-LMP1 alone, although it extended the passage number of
MEF cells, was not sufficient to induce telomerase activity.
In contrast, the MEF cells coinfected with v-LMP1 and
v-CDK4R24C were telomerase positive at P10, consistent with
the transformation properties that they acquired. The
v-CDK4R24C-infected MEF cells were not examined because
they had a limited passage history (P5), one passage longer
than that of the v-LNSX cells. The results suggest that al-
though LMP1 efficiently induces the proliferation of MEF
cells, additional changes are likely needed for the MEF-LMP1
cells to become immortal.
DISCUSSION
In the work presented here, primary BALB/c MEF cells
were used to study the proliferation and transformation func-
tions of the EBV transforming gene encoding LMP1. MEF
provides a model system free of any genetic mutation that may
complicate the results of the study, and it is commonly used as
a well-defined system to study the effects of oncogenes in
growth stimulation and cell transformation. An LMP1-express-
ing retrovirus was used to stably introduce LMP1 into MEF
cells at a high efficiency and allow us to monitor the entire
population of infected MEF cells immediately and continu-
ously throughout the course of the experiment without any
drug selection. As a result of this new approach, LMP1 was
found to have a mitogenic effect on MEF cells, as indicated by
an immediate increase in cell growth rate. In addition, while
MEF cells undergo only a few passages, the v-LMP1-infected
MEF cells can be readily subcultured for up to 30 passages,
indicating that LMP1 stimulates the long-term proliferation of
MEF cells. Furthermore, LMP1 cooperates with CDK4R24C in
transforming MEF cells, suggesting that LMP1 is capable of
cooperatively transforming primary rodent fibroblast cells with
a cellular oncogene.
Although LMP1 is essential for EBV-mediated B-cell im-
mortalization, this is the first demonstration that the LMP1
gene acting alone is sufficient to induce the proliferation of
primary culture cells. The ability of LMP1 to induce cell pro-
liferation may be important in our understanding of EBV-
associated malignancies. Previous experiments showed that in
addition to a tight association between nasopharyngeal carci-
noma and EBV, most of the cancer cells came from clonal
expansions of single EBV-infected progenitor cells (38), sug-
gesting that the presence of EBV may provide the initial and
fundamental drive in the process leading to the development of
nasopharyngeal carcinoma. At present, the ability of a single
LMP1 gene to induce the proliferation of primary culture cells
is restricted to the model system of murine fibroblasts. It is
obviously of interest to examine whether this LMP1 retrovirus
is sufficient to induce the proliferation of primary human epi-
thelial cells. It is well known, however, that LMP1 is not suf-
ficient to immortalize primary B cells. Nonetheless, the system
of LMP1-induced MEF proliferation should provide a unique
basis for addressing roles and mechanisms of LMP1 as the sole
EBV gene in cell proliferation and cell cycle regulation.
A variety of different DNA oncogenic viruses, including
SV40, adenovirus, and papillomavirus, are capable of immor-
talizing primary rodent fibroblast cells. Two functions are fre-
quently needed for these viruses to induce the immortalization
of primary cells, the inactivation of Rb, and the suppression of
p53 activities through direct interactions. SV40 large T antigen
effectively induces the immortalization of primary rodent fi-
broblasts. In addition to its binding to pRb protein, the inter-
action between T antigen and tumor suppressor p53 is also
essential for the immortalization (47, 53). In comparison, both
adenovirus E1A and HPV E7, although capable of transform-
ing immortalized rodent fibroblast cell lines, do not effectively
immortalize primary cells without the additional partners, ad-
enovirus E1B and HPV E6, respectively (16, 50, 52). The
balance between proliferation and abrogation of cell cycle
checkpoint is an important feature of these DNA oncogenic
viruses. In all of these cases, the viral proteins interfere with
the functions of the p53 tumor suppressor to prevent cell cycle
checkpoint arrest and apoptosis induced by Rb inactivation.
Our data here show that LMP1 is sufficient to effectively in-
duce the proliferation of primary MEF cells, suggesting that
LMP1 could have multiple functions in growth stimulation and
in prevention of cell cycle arrest or apoptosis induced by ab-
normal proliferation.
Many studies indicated that the expression of viral or cellu-
lar oncogenes often leads to cell cycle arrest, apoptosis, and
cell senescence that are in part dependent on p53 and its
related cell cycle checkpoints (26, 35). For example, the ex-
pression of adenovirus E1A in primary fibroblast cells results
in the stabilization of p53 and the induction of apoptosis (10,
29). Therefore, the ability to neutralize p53 is an essential
feature of many DNA oncogenic viruses. The p53-binding do-
main of SV40 T antigen is essential for T antigen to immor-
talize and transform cells (47, 53). Similarly, both the E1B
55-kilodalton protein of adenovirus and E6 of HPV can inhibit
the activity of p53 through direct interactions and, in the case
FIG. 5. LMP1 increase the growth rate of MEF cells. MEF cells were freshly
infected with v-LNSX (diamonds) or v-LMP1 (squares). After infection, the cells
were removed from the plates with trypsin digestion at the end of P1; approxi-
mately 2,000 cells were plated in each well of 24-well plates in triplicate at day 0
and incubated further at 37°C. At the indicated time points, the cells were
removed from the plates with trypsin and counted. The average numbers of cells
at each time point was determined, and their standard derivations were obtained
and plotted.
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of E6, the degradation of p53 protein (44, 52). Interestingly,
the E1B 19-kDa protein is a homologue of Bcl-2 (4), encoded
by a gene that was shown to be induced by LMP1 (17). Our
results raised the possibility that LMP1 can also affect cell cycle
checkpoints in the process of achieving primary cell prolifera-
tion. Previous experiments show that LMP1 is capable of
inducing the expression of Bcl-2 (17, 43), activating NF-kB
activity (19, 32), and up-regulating the expression of an anti-
apoptotic gene, A20 (27). All of these activities have been
linked to suppression of cell apoptosis. Indeed, two studies
directly demonstrate the roles of LMP1 in suppressing apopto-
sis induced by p53 (13, 37). We speculate, based on the ability
of LMP1 to induce cell proliferation without cell apoptosis or
growth arrest, that the roles of LMP1 in suppressing cell death
or checkpoint arrest may also be an important part of LMP1
functions to induce a coordinated cellular proliferation of pri-
mary cells. We are currently investigating the roles of LMP1 in
altering the regulation of genes involved in cell cycle control
and checkpoint regulation.
Although LMP1 induces the proliferation of MEF cells, it is
not sufficient to induce telomerase activity. In fact, no telom-
erase activity was observed in LMP1-induced proliferative
MEF cells at P10. This result is consistent with a previous
finding that in human B cells transformed with EBV, shorten-
ing of telomeres occurred in all EBV-positive populations until
chromosomes had little telomeric DNA remaining. At this
stage, many clones entered into a proliferative crisis and died,
leaving only those with activated telomerase capable of prolif-
erating indefinitely (9).
The exact mechanisms by which LMP1 induces cellular
transformation are still under investigation. Two recent studies
indicate that LMP1 is involved in induction of JNK (11, 25).
The results also indicate that the LMP1-mediated JNK path-
way appears to differ from the LMP1-induced NF-kB pathway.
FIG. 6. Cooperative transformation of MEF cells by LMP1 and CDK4R24C. A soft agar assay was performed with cells infected with v-LNSX (A), v-LMP1 (B),
v-H-rasV12 (C), v-LMP1 plus v-H-rasV12 (D), v-CDK4R24C (E), or v-LMP1 plus v-CDK4R24C (F). The cells at P6 were used for cells infected with v-LMP1 (B), v-LMP1
plus v-H-rasV12 (D), and v-LMP1 plus v-CDK4R24C (F). Cells at P3 were used for the other three cultures due to their limited passage numbers (P5 or less). The foci
were counted in two independent experiments (see Results).
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However, it is not clear that either pathway can explain the
roles of LMP1 during its transformation process. Another re-
cent study reveals that LMP1 can activate the Ras pathway
(40). The activated Ras was shown to up-regulate cyclin D1,
resulting in the inactivation of Rb through phosphorylation
(41). Interestingly, a previous study shows that oncogenic Ras
but not Myc can transform primary mouse fibroblast cells de-
ficient for the p16 gene (45), suggesting such a cooperation
may be mediated through the p16/CDK4/D1-to-pRb pathway.
Analysis of the cooperation between the LMP1 gene and other
oncogenes in inducing the transformation of primary fibroblast
cells may provide a genetic model system for evaluating the
roles of LMP1 and its activated pathways in the process of
LMP1-mediated cellular transformation. Our results indicate
that the LMP1 gene cooperates with CDK4R24C but not H-
rasV12 in transforming MEF cells. The results are consistent
with the notion that LMP1 may exert its transformation func-
tion through a Ras-related pathway. They are also in agree-
ment with previous studies indicating that Ras readily induces
the malignant transformation of MEF cells established from
p16INK4a knockout mouse and cooperates with a CDK4R24C
mutant in transforming MEF cells (45, 46).
It is worth noting that the cooperative transformation pro-
cess with v-LMP1 and v-CDK4R24C may be different from
v-LMP1-induced proliferation. The first sign of morphological
transformation required 2 to 3 weeks with more passages, and
it was found for only a very small percentage of infected cells
analyzed for focus formation on plates (4 and 19 in two exper-
iments). Alternatively, it is possible, although not very likely
based on the viral titers, that only a small percentage of cells
have both viruses and expressed both proteins. Nonetheless,
the transformed cells induced by LMP1 and CDK4R24C quickly
took over the entire population. The LMP1- and CDK4R24C-
transformed MEF cells present a distinct morphology that is
characteristic of the transformed cells. In addition, they form
foci in the soft agar assay, indicative of anchorage-independent
growth. Furthermore, they are positive for the telomerase ac-
tivity that is absent in the proliferative MEF-LMP1 cells. In sum,
EBV is a DNA oncogenic virus, and LMP1 appears to be capable
of inducing the proliferation of primary MEF cells and coopera-
tively transforming them with another cellular oncogene.
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